跳至主要内容
临床试验/NCT03386890
NCT03386890Unknown不适用

Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis

Beijing Friendship Hospital1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2015年12月最近更新:
适应症

试验速览

阶段
不适用
入组人数
400
试验地点
1
主要终点
CAP

研究概览

简要总结

Nowadays, the morbidity of Nonalcoholic fatty liver disease (NAFLD) show ascending trend year by year, which has become an important public health problem in China. As NAFLD can progress to Non-alcoholic steatohepatitis (NASH), cirrhosis and Hepatocarcinoma, the identification and quantitative evaluation of liver steatosis and its dynamic changes are crucial. While liver biopsy is still the gold standard in the diagnosis of NAFLD, its application is limited because of the invasive procedure.The Transient Elastography(TE) combined with the Controlled Attenuation Parameter(CAP) is a new non-invasive diagnostic method for fatty liver and liver fibrosis.

In order to evaluate the diagnostic value of non-invasive assessment for the degree of liver steatosis and staging liver fibrosis, this non-invasive method will be assessed by the golden standard of liver biopsy among 400 NAFLD patients.The treatment protocols will be decided by doctor and patient both (treatment protocols and medicine are not required). Blood routine, blood biochemistry, abdominal ultrasound and Transient Elastography(TE) combined with the Controlled Attenuation Parameter(CAP) are detected during the follow-up.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age:18≤,≥65
  • Gender:male or female
  • NAFLD patient,agree with the paracentesis of liver tissue
  • Regular follow-up
  • Signing the Informed Consent Form

排除标准

  • Hepatic decompensation:Including cirrhotic complications,such as ascites,hepatic encephalopathy,digestive tract bleeding,hepatorenal syndrome,spontaneous bacterial peritonitis,and HCC.
  • Complications of HBV,HCV,HIV.Complications of alcoholic liver disease,autoimmune liver disease,hereditary metabolic liver disease, drug-induced liver disease and other chronic liver disease.
  • AFP>100ng/ml and imaging indicates malignant occupying.Or AFP still>100ng/ml within 3 months.
  • Creatinine was 1.5 times higher than the upper limit of the normal value.
  • Combined with other malignant tumors(except those cured).
  • Serious diseases of heart, lung, kidney, brain, blood and other important organs with dysfunction.
  • severe neurological and psychiatric diseases (such as epilepsy, depression, mania, schizophrenia, etc.)
  • Pregnant women and breast-feeding women.
  • The researchers consider that it is not suitable for the patients to participate in this study.

结局指标

主要结局

CAP

时间窗: 1 year

Controlled Attenuation Parameter

TE

时间窗: 1 year

Transient Elastography

Liver Biopsy

时间窗: 1 year

liver histological section

次要结局

  • kidney function test(1 year)
  • electrolyte(1 year)
  • Blood routine test(1 year)
  • blood glucose(1 year)
  • blood lipid(1 year)
  • liver biochemistry test(1 year)
  • abdominal ultrasound(1 year)
  • uric acid(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jidong Jia

Chief Physician

Beijing Friendship Hospital

研究点 (1)

Loading locations...

相似试验

Clinical Application of Non-invasive Assessment for... | 临床试验